SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our observations demonstrate that the functional contribution of SOS1 is critically required for CML pathogenesis and support the consideration of this particular cellular GEF as a novel and alternative therapeutic target for CML, which might be particularly useful in cases where drug resistances frequently arise after sustained clinical treatment with imatinib or other TKI inhibitors.